VK2735 for Obesity (VENTURE Trial)

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Viking Therapeutics, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a treatment called VK2735 to help adults who are overweight or obese lose weight. The study focuses on people who also have other health issues related to their weight. Researchers want to see if VK2735 is safe and effective for weight loss.

Eligibility Criteria

This trial is for adults over 18 with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition, but not heavier than a BMI of 50. It's not for those who've had significant weight changes recently, have diabetes or chronic pancreatitis, used certain drugs for weight loss in the past 6 months, or have specific medical conditions that could affect their participation.

Inclusion Criteria

I am 18 years old or older.

Exclusion Criteria

I have been diagnosed with chronic pancreatitis.

I have been diagnosed with diabetes.

Treatment Details

The study tests VK2735 against a placebo to see if it's safe and effective for weight loss. Participants will be randomly assigned to receive either VK2735 or a placebo once weekly for 13 weeks while researchers track safety, how well it works, and how the body processes the drug.

5Treatment groups

Experimental Treatment

Placebo Group

Group I: VK2735 (Dose #4)Experimental Treatment1 Intervention

VK2735 is a peptide GLP-1 and GIP dual agonist

Group II: VK2735 (Dose #3)Experimental Treatment1 Intervention

VK2735 is a peptide GLP-1 and GIP dual agonist

Group III: VK2735 (Dose #2)Experimental Treatment1 Intervention

VK2735 is a peptide GLP-1 and GIP dual agonist

Group IV: VK2735 (Dose #1)Experimental Treatment1 Intervention

VK2735 is a peptide GLP-1 and GIP dual agonist

Group V: VK2735 (Placebo)Placebo Group1 Intervention